Cell death pathways represent critical final common mechanisms in 4-repeat (4R) tauopathies, where the progressive accumulation of hyperphosphorylated 4R tau in neurons and glia ultimately leads to neurodegeneration. Understanding how apoptosis and necroptosis contribute to neuronal loss in progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) provides essential insights into disease pathogenesis and identifies potential therapeutic targets. While these diseases share the common feature of 4R tau aggregation, the specific cell death pathways activated and their relative contributions vary depending on the tau strain, cellular vulnerability, and regional pathology patterns.
The 4R-tauopathies comprise a group of neurodegenerative disorders characterized by the preferential accumulation of tau isoforms containing four microtubule-binding repeats (4R tau)[1]. This stands in contrast to Alzheimer's disease, where both 3R and 4R tau isoforms aggregate in neurofibrillary tangles. The specific inclusion of 4R tau isoforms arises from alternative splicing of exon 10 of the MAPT gene, which is regulated by various splicing factors and can be influenced by mutations in FTDP-17[2].
Despite their classification as distinct diseases, 4R-tauopathies share several key pathological features that trigger cell death pathways:
Two primary programmed cell death pathways contribute to neurodegeneration in 4R-tauopathies:
The relative activation of these pathways differs across the various 4R-tauopathies and even among different neuronal populations within a single disease, creating a complex landscape of cell death mechanisms that must be understood to develop effective neuroprotective therapies.
Apoptosis in 4R-tauopathies involves both intrinsic (mitochondrial) and extrinsic (death receptor) pathways, with evidence suggesting that both pathways contribute to neuronal loss in varying degrees depending on the specific disease and disease stage.
The Bcl-2 family of proteins serves as critical regulators of the intrinsic apoptotic pathway, functioning as either pro-apoptotic or anti-apoptotic molecules that control mitochondrial outer membrane permeabilization (MOMP)[4]. In 4R-tauopathies, dysregulation of these proteins contributes to mitochondrial dysfunction and apoptosis.
Anti-apoptotic members (elevated as compensatory response):
Pro-apoptotic members (activated by tau pathology):
Tau pathology directly impairs mitochondrial function through multiple mechanisms[5]:
In PSP, mitochondrial complex I deficiency has been documented in the substantia nigra[6], contributing to the characteristic dopaminergic neuron loss. Similar findings have been reported in CBD, where mitochondrial dysfunction correlates with disease severity.
When MOMP occurs in 4R-tauopathies, cytochrome c is released from the mitochondrial intermembrane space, binding to Apaf-1 and ATP to form the apoptosome[7]. This complex recruits and activates procaspase-9, initiating the caspase cascade that leads to executioner caspase activation and cell death.
Neurons in 4R-tauopathies exhibit altered expression of death receptors:
Caspase-8 activation at the death-inducing signaling complex (DISC) can directly activate executioner caspases or cleave Bid to tBid, linking extrinsic to intrinsic apoptosis. This cross-talk amplifies the apoptotic signal in tauopathy neurons.
Multiple caspases are activated in 4R-tauopathies, each contributing to different aspects of neuronal death:
The major executioner caspase, caspase-3 is consistently activated in 4R-tauopathies[8]:
Caspase-3 cleaves numerous substrates including:
Caspase-6 is particularly relevant in tauopathies due to its ability to cleave tau protein[9]:
Caspase-cleaved tau fragments:
Caspase-9 activation reflects engagement of the intrinsic apoptotic pathway[10]:
Extrinsic pathway activation involves caspase-8[11]:
PSP demonstrates a characteristic pattern of apoptosis that correlates with its clinical phenotype[12]:
Affected Regions:
Molecular Features:
Selective Vulnerability:
CBD exhibits apoptosis patterns reflecting its asymmetric cortical and basal ganglia pathology[13]:
Affected Regions:
Molecular Features:
Astrocystic and Microglial Involvement:
AGD shows a somewhat distinct apoptotic pattern, reflecting its characteristic pathology[14]:
Affected Regions:
Molecular Features:
Characteristic Pattern:
GGT demonstrates unique apoptosis mechanisms due to its glial-predominant pathology:
Affected Regions:
Molecular Features:
Glial-Neuronal Interactions:
FTDP-17 shows variable apoptosis patterns depending on the specific MAPT mutation[15]:
Affected Regions:
Mutation-Specific Patterns:
Molecular Features:
Necroptosis has emerged as an important contributor to neurodegeneration in 4R-tauopathies, offering a potential explanation for the inflammatory component of these diseases and providing additional therapeutic targets.
RIPK1 (Receptor-Interacting Protein Kinase 1)
RIPK3 (Receptor-Interacting Protein Kinase 3)
MLKL (Mixed Lineage Kinase Domain-Like)
Tau pathology can activate necroptosis through multiple mechanisms[19]:
RIPK1 and RIPK3 activation has been documented in PSP brain tissue[20]:
CBD shows similar necroptosis activation patterns:
Less direct evidence exists for AGD, GGT, and FTDP-17, though:
Necroptotic cells release damage-associated molecular patterns (DAMPs) that propagate inflammation:
The inflammatory consequences of necroptosis create feed-forward loops[21]:
| Compound | Target | Therapeutic Potential |
|---|---|---|
| Necrostatin-1 | RIPK1 | Preclinical in PSP/CBD models |
| Necrostatin-1s | RIPK1 | Improved brain penetration |
| GSK'872 | RIPK3 | Research tool |
| MLKL inhibitors | MLKL | Early development |
Targeting both apoptosis and necroptosis may provide enhanced neuroprotection:
Different 4R-tau strains (structural variants) influence cell death pathway activation, explaining the heterogeneity among 4R-tauopathies.
Cryo-EM studies have revealed distinct tau filament structures in different 4R-tauopathies[22]:
Different tau strains activate distinct cell death pathways:
PSP strains:
CBD strains:
AGD strains:
Understanding strain-specific cell death mechanisms allows for personalized approaches:
| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---|---|---|---|---|---|
| Intrinsic pathway | +++ | +++ | ++ | ++ | +++ |
| Extrinsic pathway | ++ | +++ | + | ++ | ++ |
| Caspase-3 | +++ | +++ | ++ | ++ | ++ |
| Caspase-6 | +++ | +++ | ++ | ++ | +++ |
| Caspase-9 | ++ | ++ | + | + | ++ |
| Bcl-2 family | Dysregulated | Dysregulated | Variable | Variable | Mutation-dependent |
| Mitochondrial dysfunction | +++ | +++ | ++ | ++ | +++ |
| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---|---|---|---|---|---|
| RIPK1 activation | +++ | ++ | + | + | ++ |
| RIPK3 activation | ++ | ++ | + | + | + |
| MLKL activation | ++ | + | + | + | + |
| DAMP release | +++ | +++ | ++ | ++ | ++ |
| Inflammatory component | +++ | +++ | ++ | ++ | +++ |
| Necrostatin benefit | ++ | ++ | + | + | ++ |
Goedert M, et al. The tauopathies: Biology and pathology. Nature Reviews Neuroscience. 2018. ↩︎
Baker M, et al. Association of MAPT mutations with 4R-tauopathies. Nature. 1999. ↩︎
Spillantini MG, et al. Tau pathology in FTDP-17. Annals of Neurology. 2000. ↩︎
Chen L, et al. Bcl-2 family in tauopathies. Cell Death & Disease. 2014. ↩︎
Feinstein KJ, et al. Tau aggregation and mitochondrial apoptosis. Neurobiology of Aging. 2019. ↩︎
Williams DR, et al. Neuropathology and biomarker profiles in progressive supranuclear palsy. Brain. 2019. ↩︎
Raitano AB, et al. Bcl-2 family and tau pathology. Cell Death Discovery. 2015. ↩︎
Colombo G, et al. Caspase-3 activation in tauopathies. Cell Death & Differentiation. 2019. ↩︎
Davis J, et al. Caspase-cleaved tau in PSP. Acta Neuropathologica. 2018. ↩︎
Martinez F, et al. Caspase activation in PSP. Journal of Alzheimer's Disease. 2019. ↩︎
Kelley EJ, et al. Caspase-6 in CBD. Acta Neuropathologica Communications. 2019. ↩︎
Tokutake Y, et al. Apoptosis in 4R-tauopathies. Journal of Neuropathology & Experimental Neurology. 2015. ↩︎
Ishida C, et al. Neuronal apoptosis in CBD. Acta Neuropathologica. 2013. ↩︎
Yoshida M, et al. Argyrophilic grain disease pathology. Neuropathology. 2019. ↩︎
Matsuo H, et al. Tau mutations in FTDP-17. Science. 1998. ↩︎
Ofengeim D, et al. RIPK1 activation in tauopathies. Neuron. 2017. ↩︎
Ito Y, et al. RIPK3 in neuronal death. Science. 2016. ↩︎
Wang Y, et al. MLKL in neurodegeneration. Cell Reports. 2018. ↩︎
Kovacs M, et al. Tauopathies and necroptosis signaling. Brain Pathology. 2019. ↩︎
Onishi M, et al. RIPK1 inhibition in 4R-tauopathies. Neurobiology of Disease. 2019. ↩︎
Moriwaki K, et al. Necroptosis and inflammation in brain. Trends in Neurosciences. 2017. ↩︎
Bote C, et al. Tau strains and cell death. Brain. 2019. ↩︎